Karuna Therapeutics

The company's primary business centers on the research, development, and commercialization of novel therapies. Its target market is the vast and underserved population suffering from central nervous system (CNS) disorders. Karuna's business model is typical of a biopharmaceutical firm, involving significant investment in research and development, funded by venture capital and public offerings, with the goal of generating revenue through the sale of approved drugs.

A significant milestone for the company was the acquisition of its lead product candidate, KarXT, from PureTech Health. KarXT (xanomeline-trospium) is an oral medication designed to treat psychosis in adults with schizophrenia. The product works by selectively activating muscarinic acetylcholine receptors in the brain, a different mechanism from existing schizophrenia treatments. This novel approach aims to provide a new therapeutic option for patients. In a major development, Karuna Therapeutics was acquired by Bristol Myers Squibb in a transaction valued at $14 billion, which was completed in March 2024. This acquisition positions Karuna's pipeline within a larger pharmaceutical entity, potentially accelerating the path to commercialization. The U.S. Food and Drug Administration (FDA) has set a Prescription Drug User Fee Act (PDUFA) date of September 26, 2024, for a decision on KarXT's New Drug Application for the treatment of schizophrenia in adults.